Conventional approaches to relieve dyspnea (respiratory discomfort) in chronic obstructive pulmonary disease (COPD) have focused on improving respiratory motor drive (e.g., hyperoxia) and/or dynamic respiratory mechanics (e.g., bronchodilators). Although these approaches yield meaningful symptom improvements there remains many COPD patients incapacitated by dyspnea. Accumulating evidence suggests that abdominal binding (AB) is a potentially novel method of improving respiratory muscle function and, by extension, dyspnea and exercise tolerance in COPD. Thus, the purpose of this randomized, cross-over study is to test the hypothesis that AB improves exertional dyspnea and exercise tolerance in symptomatic patients with COPD by improving dynamic respiratory muscle function. To this end, the investigators will examine the effects of AB on detailed assessments of baseline pulmonary function (spirometry, plethysmography), dyspnea (sensory intensity \& affective responses), neural respiratory drive (diaphragm EMG), contractile respiratory muscle function (esophageal, gastric \& transdiaphragmatic pressures), ventilation, breathing pattern and cardiometabolic function during symptom-limited constant load cycle exercise (75% Wmax) in 20 patients with GOLD stage II/III COPD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
Montreal Chest Institute; McGill University Health Center & McGill University
Montreal, Quebec, Canada
Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime during exercise
Time frame: Patients will be followed until all study visits are complete, an expected average of 2 weeks
Exercise Endurance Time (EET)
Time frame: Patients will be followed until all study visits are complete, an expected average of 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.